AbbVie Inc., North Chicago, Illinois, USA.
Merck & Co., Kenilworth, New Jersey, USA.
Clin Pharmacol Ther. 2018 Jul;104(1):88-110. doi: 10.1002/cpt.1013. Epub 2018 Feb 2.
This work provides a perspective on the qualification and verification of physiologically based pharmacokinetic (PBPK) platforms/models intended for regulatory submission based on the collective experience of the Simcyp Consortium members. Examples of regulatory submission of PBPK analyses across various intended applications are presented and discussed. European Medicines Agency (EMA) and US Food and Drug Administration (FDA) recent draft guidelines regarding PBPK analyses and reporting are encouraging, and to advance the use and acceptability of PBPK analyses, more clarity and flexibility are warranted.
本工作基于 Simcyp 联盟成员的集体经验,就用于监管提交的基于生理学的药代动力学(PBPK)平台/模型的资格认证和验证提供了一个视角。本文介绍和讨论了各种预期应用的 PBPK 分析的监管提交示例。欧洲药品管理局(EMA)和美国食品和药物管理局(FDA)最近发布的关于 PBPK 分析和报告的指南草案令人鼓舞,为了推进 PBPK 分析的使用和接受度,需要更明确和灵活。